Contact Us (781) 301-7474

Hemanext is a privately held medical technology company dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored red blood cells (RBCs).

LEARN ABOUT BLOOD QUALITY:

Educational Symposiums
Key Abstracts and Publications

Patient Advocacy Groups

RECENT NEWS: AABB RISE AWARD

Hemanext

CONGRATULATES THE AUTHORS OF THE 2021 RISE AWARD

Click to See Full Ad

HEMANEXT INC. announced that AABB, a leading international body involved in transfusion medicine and biotherapies, has given its Research Innovation in Scientific Excellence (RISE) award to a scientific paper co-written by the company’s Chief Scientific Officer, Andrew Dunham, PhD, and Principal Scientist, Tatsuro Yoshida, PhD.

READ MORE >>

AABB’S CORPORATE PARTNER PROGRAM focuses on celebrating the vital work of corporate members of the blood and biotherapies community.

CONNECT WITH HEMANEXT TODAY TO LEARN MORE!

We are happy to answer any questions about the company, our technology, or our research. Fill out the form below and we will connect with you!

Privacy


We use cookies to understand how you use our site and to improve your experience. This includes personalizing content. To learn more, click here.